University of Washington has divulged compounds acting as methionyl-tRNA synthetase (bacterial) inhibitors reported to be useful for the treatment of bacterial and protozoal infections.

Independent data and safety monitoring board (DSMB) review includes all 268 patients who have been enrolled in the study and ...

SAN DIEGO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR), a clinical stage biotechnology company engaged in the discovery ...

Tyr Pharma (ATYR) announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone ...

SAN DIEGO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from ...

SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-cla ...